Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study of Danavorexton in Anesthetized Adults

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Danavorexton
Drug: Danavorexton Placebo
Drug: Propofol
Drug: Sevoflurane

First Posted Date: 2021-08-27

Last Posted Date: 2022-05-10

Lead Sponsor: Takeda

Target Recruit Count: 28

Registration Number: NCT05025397

Locations: 🇺🇸
Endeavor Clinical Trials, San Antonio, Texas, United States

A Study of Teduglutide in Japanese People With Short Bowel Syndrome

Recruiting

Conditions: Short Bowel Syndrome

Interventions: Drug: Teduglutide

First Posted Date: 2021-08-26

Last Posted Date: 2024-05-29

Lead Sponsor: Takeda

Target Recruit Count: 120

Registration Number: NCT05023382

Locations: 🇯🇵
Takeda Selected Site, Tokyo, Japan

A Study of Niraparib in Patients with Ovarian Cancer in Clinical Practice

Recruiting

Conditions: Ovarian Cancer

Interventions: Drug: Niraparib

First Posted Date: 2021-08-25

Last Posted Date: 2024-11-13

Lead Sponsor: Takeda

Target Recruit Count: 300

Registration Number: NCT05021562

Locations: 🇯🇵
Takeda Selected Site, Tokyo, Japan

A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Phase 2

Active, not recruiting

Conditions: Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Interventions: Biological: TAK-007
Drug: Chemotherapy Agents

First Posted Date: 2021-08-25

Last Posted Date: 2024-05-29

Lead Sponsor: Takeda

Target Recruit Count: 27

Registration Number: NCT05020015

Locations: 🇺🇸
Cedars Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States

and more 12 locations

A Study of NINLARO® in Chinese Adults With Multiple Myeloma

Recruiting

Conditions: Multiple Myeloma

Interventions: Other: No intervention

First Posted Date: 2021-08-19

Last Posted Date: 2024-06-05

Lead Sponsor: Takeda

Target Recruit Count: 320

Registration Number: NCT05013190

Locations: 🇨🇳
Anhui Cancer Hospital, Hefei, Anhui, China
🇨🇳
Beijing Chao-Yang Hospital,Capital Medical University, Beijing, Beijing, China
🇨🇳
Beijing Jishuitan Hospital, Beijing, Beijing, China

and more 9 locations

Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis

Phase 2

Completed

Conditions: Moderate to Severe Plaque Psoriasis

Interventions: Drug: NDI-034858 study drug
Other: Placebo

First Posted Date: 2021-08-11

Last Posted Date: 2023-09-28

Lead Sponsor: Takeda

Target Recruit Count: 259

Registration Number: NCT04999839

Locations: 🇺🇸
Nimbus site 139, Miami Lakes, Florida, United States
🇺🇸
Nimbus site 150, Macon, Georgia, United States
🇺🇸
Nimbus site 123, Skokie, Illinois, United States

and more 66 locations

A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin

Completed

Conditions: Hodgkin Disease
Lymphoma, T-Cell, Cutaneous

Interventions: Other: No Intervention

First Posted Date: 2021-08-10

Last Posted Date: 2024-07-08

Lead Sponsor: Takeda

Target Recruit Count: 51

Registration Number: NCT04998331

Locations: 🇪🇸
Hospital Universitario de Alava, Vitoria-Gasteiz, Araba, Spain
🇪🇸
Hospital Universitario Donostia, Donostia, Gipuzkoa, Spain
🇪🇸
Hospital Universitario Son Espases, Palma de Mallorca, Mallorca, Spain

and more 27 locations

Study to Assess Absolute Bioavailability of TAK-935 (OV935) and to Characterize Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]TAK-935 (OV935) in Healthy Male Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TAK-935 Oral Tablet
Drug: [14C]TAK-935 IV Infusion
Drug: [14C]TAK-935 Oral Solution

First Posted Date: 2021-08-05

Last Posted Date: 2021-10-04

Lead Sponsor: Takeda

Target Recruit Count: 6

Registration Number: NCT04992442

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland

Completed

Conditions: Inflammatory Bowel Diseases
Crohns Disease
Colitis, Ulcerative

First Posted Date: 2021-08-04

Last Posted Date: 2024-07-19

Lead Sponsor: Takeda

Target Recruit Count: 92

Registration Number: NCT04989907

Locations: 🇨🇭
Clarunis AG, Basel, Switzerland
🇨🇭
Bauchzentrum INSELSPITAL, Universitatsspital Bern, Bern, Switzerland
🇨🇭
Gastroenterologische Praxis Balsiger, Seibold & Partner Crohn-Colitis-Zentrum, Bern, Switzerland

and more 3 locations

A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes

Phase 2

Withdrawn

Conditions: Myelodysplastic Syndromes (MDS)

Interventions: Drug: Pevonedistat
Drug: Decitabine
Drug: Cedazuridine

First Posted Date: 2021-08-02

Last Posted Date: 2021-09-29

Lead Sponsor: Takeda

Registration Number: NCT04985656

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy